Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

Details

Serval ID
serval:BIB_17E3124045E2
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
Journal
Pharmacology & therapeutics
Author(s)
Michel M.C., Brunner H.R., Foster C., Huo Y.
ISSN
1879-016X (Electronic)
ISSN-L
0163-7258
Publication state
Published
Issued date
08/2016
Peer-reviewed
Oui
Volume
164
Pages
1-81
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin-angiotensin system; blood pressure lowering even persists for a considerable time after discontinuation of treatment. This translates into a reduced mortality, particularly in models exhibiting marked hypertension. The retrieved data on vascular, cardiac and renal function and morphology as well as on glucose and lipid metabolism are discussed to address three main questions: 1. Can ARB effects on blood vessels, heart, kidney and metabolic function be explained by blood pressure lowering alone or are they additionally directly related to blockade of the renin-angiotensin system? 2. Are they shared by other inhibitors of the renin-angiotensin system, e.g. angiotensin converting enzyme inhibitors? 3. Are some effects specific for one or more compounds within the ARB class? Taken together these data profile ARBs as a drug class with unique properties that have beneficial effects far beyond those on blood pressure reduction and, in some cases distinct from those of angiotensin converting enzyme inhibitors. The clinical relevance of angiotensin receptor-independent effects of some ARBs remains to be determined.

Keywords
Angiotensin II Type 1 Receptor Blockers/pharmacology, Animals, Animals, Genetically Modified, Antihypertensive Agents/pharmacology, Atherosclerosis/drug therapy, Atherosclerosis/physiopathology, Benzimidazoles/pharmacology, Benzoates/pharmacology, Blood Pressure/drug effects, Cardiovascular Diseases/drug therapy, Cardiovascular Diseases/mortality, Cardiovascular Diseases/physiopathology, Culture Techniques, Disease Models, Animal, Drug Therapy, Combination, Endothelium, Vascular/drug effects, Endothelium, Vascular/physiopathology, Gene Knockout Techniques, Glucose/metabolism, Humans, Hypertension/drug therapy, Kidney/drug effects, Kidney/physiopathology, Lipid Metabolism/drug effects, Lipid Metabolism/physiology, Metabolic Diseases/drug therapy, Metabolic Diseases/physiopathology, Oxadiazoles/pharmacology, Renin-Angiotensin System/drug effects, Stroke/prevention & control
Pubmed
Web of science
Open Access
Yes
Create date
05/09/2017 11:48
Last modification date
20/08/2019 12:47
Usage data